2015 Group Project 1: Difference between revisions

From Embryology
Line 63: Line 63:
! Preventable with mitochondrial donation
! Preventable with mitochondrial donation
|-
|-
| Kearns-Sayre sydrome (KSS)
| Kearns-Sayre sydrome (KSS)<ref><pubmed>25539952</pubmed></ref>
| Mitochondrial Myopathy
| Mitochondrial Myopathy
| Causes ''pigmentary retinopathy'', conduction block, ataxia. Can cause mental reardation/deterioration, delayed sexual maturation.  
| Causes ''pigmentary retinopathy'', conduction block, ataxia. Can cause mental reardation/deterioration, delayed sexual maturation.  
Line 69: Line 69:
| style="background-color: lime;"|"Yes"
| style="background-color: lime;"|"Yes"
|-bgcolor="F5FAFF"  
|-bgcolor="F5FAFF"  
| Leigh syndrome<ref><pubmed>18651330</pubmed></ref>
| Mitochondrial Myopathy
| Necrotizing lesions in the brain-stem, developmental delays, muscle weakness, hypotonia, respiratory distress, death before the age of five.
| 30 X-linked Recessive genes. mtDNA mutation.
| style="background-color: LightBlue;"|"20% of Cases"
|-
| Mitochondrial DNA depletion syndrome (MDS)<ref><pubmed>23385875</pubmed></ref>
| Mitochondrial DNA depletion syndrome (MDS)<ref><pubmed>23385875</pubmed></ref>
| Mitochondrial Myopathy
| Mitochondrial Myopathy
Line 80: Line 86:
| mtDNA point mutation  
| mtDNA point mutation  
| style="background-color: lime;"|"yes"
| style="background-color: lime;"|"yes"
|-
| Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)
| Mitochondrial Myopathy
|
|
|
|-
| Myoclonus epilepsy with ragged red fibres (MERFF)
| Mitochondrial Myopathy
|
|
|
|-
| Neuropathy, ataxia and retinitis pigmentosa (NARP)
| Mitochondrial Myopathy
|
|
|
|-
| Pearson syndrome
| Mitochondrial Myopathy
|
|
|
|-
| Progressive external ophthalmoplegia (PEO)
| Mitochondrial Myopathy
|
|
|
|-
|
|
|
|
|
|}
|}


Revision as of 17:04, 22 October 2015

2015 Student Projects 
2015 Projects: Three Person Embryos | Ovarian Hyper-stimulation Syndrome | Polycystic Ovarian Syndrome | Male Infertility | Oncofertility | Preimplantation Genetic Diagnosis | Students
2015 Group Project Topic - Assisted Reproductive Technology
This page is an undergraduate science embryology student and may contain inaccuracies in either description or acknowledgements.

Three Person Embryos

Three Person Embyo is a form of germline fertility treatment by which an oocyte are formed containing maternal and paternal DNA and donated mitochondrial DNA (mtDNA). This can be with the presence or absence of maternal mtDNA. The purpose of this treatment is to prevent the maternal inheritance of hereditary mitochondrial diseases and treat some forms of infertility caused by mtDNA mutation. It is also referred to as Mitochondrial Donation and Mitochondrial replacement-assisted IVF.

<html5media width="560" height="315">https://www.youtube.com/embed/0Zs2KntZ7vU</html5media>

Teenage Girl Has Three Biological Parents [1]

History

Timeline Of Mitochondrial Donation

1980s

  • 1982, United Kingdom - Audrey Muggleton-Harris's group at MRC Laboratory Animals Center in Surrey, developed the technique and reported the first successful mammalian cytoplasmic transfer in mice [2].
  • 1982 United Kingdon - Muggleton-Harris's group transferred cytoplasm from mice strains whose oocytes divide past the two-cell stage in vitro into mice to overcome the two-cell barrier [3].
  • 1984 Publication of the UKs Warnock Report on IVF technologies and embryo research in reaction to 1978s first IVF baby. Becomes blueprint for regulation.
  • 1988 First pathogenic mitochondrial mutations in humans identified [4][5]

1990s

  • 1996 Dolly the sheep born from nuclear transfer. Generates public interests in genetic modification and clinical embryology[6].
  • 1997, United States - Jacques Cohen, Richard Scott, Tim Schimmel, Jacob Levron, and Steen Willadsen at the Institute for Reproductive Medicine and Science of St. Barnabas in West Orange, New Jersey, announced the birth of a baby girl after the first successful human cytoplasmic transfer [7].
  • 1997 St Barnabas Hospital announces it has achieved a live birth from mitochondrial donation via Ooplasmic transfer [8]
  • 1998 FDA ban use of Ooplasmic transfer techniques in the USA
  • 1998 First oocyte with DNA transferred from a first polar body fertilized brought to term in a mouse model. [9]

2000s

  • 2002 United States - one of the children conceived through ooplasmic transfer were diagnosed with pervasive developmental disorder, and indicated mild developmental delays to severe autism.
  • 2008 Nov 13th The Human Fertilization and Embryology Act allows research into the techniques of three person IVF.
  • 2009 First success-full trails spindle transfer in rhesus monkeys [10]

2010s

  • 2010 Craven et al pronuclear transfer and mitochondrial DNA disorder prevention.[11]
  • 2014 United States - public meetings to discuss mitochondrial manipulation techniques were held by FDA. There was no formal decision made base on the efficacy of Cytoplasmic transfer, but agreements were made on further practice on animal models to provide scientific data.
  • 2015 Oct 29th regulations to allow the open use of three person IVF via pronuclear transfer in fertility clinics comes into affect in the UK.

Benefits

Mitochondria are generally known as the ATP production sites of the cell. Although they are also involved in signalling, differentiation, cell cycle, cell development, Neuronal function and many other functions [12]. In mammals mitochondria contain their own circular genome encoding for 37 genes of which 13 are vital to oxidative phosphorylation and hence the respiratory chain. The remainder of mtDNA encodes for tRNAs and rRNAs[13]. Each mitochondria contain 2-10 identical copies of their mtDNA at birth in a healthy person and average 100 mitochondria per cell. In addition to mtDNA over 1000 nuclear DNA encoded genes have so far been identified as involved in the life-cycle and function of mitochondria[14].

Mitochondrial donation can benefit anyone that is at risk of passing on to their offspring a mitochondrial disorder that is caused by a mtDNA mutation. Because mitochondrial replacement is a germ line treatment any future generations will also be free from mtDNA mutations. Extrapolation from small studies estimate that 152 women in the UK and 778 in the United State, are at risk of passing on mtDNA disorders[15].

cad pic of disease and heredisity

Risks of passing on a mitochondrial disorder

Mitochondria genome passage between generations

Mitochondria linked Infertility

can they affect fertility https://embryo.asu.edu/pages/ooplasmic-transfer-technology http://www.ncbi.nlm.nih.gov.wwwproxy0.library.unsw.edu.au/pubmed/12470582

Hereditory mitochndrial Disorders

Mitochondrial disorder Disease Type Clinical Pathology Mutation Preventable with mitochondrial donation
Kearns-Sayre sydrome (KSS)[16] Mitochondrial Myopathy Causes pigmentary retinopathy, conduction block, ataxia. Can cause mental reardation/deterioration, delayed sexual maturation. mtDNA deletion "Yes"
Leigh syndrome[17] Mitochondrial Myopathy Necrotizing lesions in the brain-stem, developmental delays, muscle weakness, hypotonia, respiratory distress, death before the age of five. 30 X-linked Recessive genes. mtDNA mutation. "20% of Cases"
Mitochondrial DNA depletion syndrome (MDS)[18] Mitochondrial Myopathy Causes muscle weakness, liver failure and developmental retardation. Can cause brain abnormalities, pigmentary retinopathy and seizures. nDNA mutation "No"
Mitochondrial encephalomyopathy, lactic acidosis and stoke-like episodes (MELAS)[19] Mitochondrial Myopathy Prolonged focal seizures and epilepsia. Pigmentary retinopathy, muscle weakness, hearing loss,diabetes. mtDNA point mutation "yes"
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) Mitochondrial Myopathy
Myoclonus epilepsy with ragged red fibres (MERFF) Mitochondrial Myopathy
Neuropathy, ataxia and retinitis pigmentosa (NARP) Mitochondrial Myopathy
Pearson syndrome Mitochondrial Myopathy
Progressive external ophthalmoplegia (PEO) Mitochondrial Myopathy

Technical Progression

Three-person in-vitro fertilization is a process where a small proportion of genetic information encoded within mitochondria are replaced to prevent mitochondrial disease passing through generations. Main approaches to achieve this goal involve the replacement of mitochondrial genome between gametes or embryos [20] [21].

  • The first proposed treatment is cytoplasmic transfer, which transfers a small part of ooplasm from one oocyte to another. however, this approach are then considered to be inadequate to prevent the inheritance of diseased mitochondrial. because it adds in donor mitochondria without removing the mutated mtDNA, which will then generate a 'heteroplasmic oocyte' with both mitochondria haplotypes [22].
  • New emerged approaches of mitochondrial transmission are pronuclear transfer(PNT), spindle transfer (ST) and Polar body transfer (PBT). however, none of this techniques have been proved on generating healthy human offspring due to the technical difficulty, as well as the ethics issues being recognized worldwide [23].
  • Major breakthroughs of these techniques rely on the practice on animal models (mice and primate) [24], early stage human embryo and stem cell studies [25].


Image Source: http://www.popsci.com.au/science/medicine/what-3parent-babies-mean-for-the-future-of-reproductive-medicine,400376

Cytoplasmic Transfer

Cytoplasmic transfer is also named Ooplasmic transfer. It is an in vitro fertilization (IVF) technique,which introduce a small amount of ooplasm from a donor oocyte or zygote into compromised oocyte or zygote from patients.

Why do cytoplasmic transfer?

The quality of the oocyte cytoplasm is critical for the future of the embryo [26].Following ovulation, the survival of zygote depends almost exclusively on maternal messenger RNA and proteins that accumulated during oocyte growth and maturation within the ooplasm. it is until the maternal-to-zygotic transition (MZT) stage during the 4–8‐cell stage in humans where the new zygote genome is activated and replace the maternal cytoplasm to be predominant in regulating the zygote development [27] . the maternal transcripts are thus responsible for the first few cleavage divisions and for transition of the maternally controlled zygote into an activated embryonic genome [28].

Researches are still underway to investigate the molecular and cellular mechanisms how ooplasm regulates the maturation and activation of human oocytes and zygotes[29]. The ooplasmic factors involved in this regulation are messenger RNA, maternally stored proteins, stockpiles of energy substrates, other energy-production components and many factors yet to be determined. The benefits of ooplasm transfer are revealed by the following two hypothesized biochemical mechanisms: correction of a putative imbalance between anti-and pro-apoptotic factors and/or correction of defective mitochondrial membrane potential[30].

What is the procedure?

Cytoplasmic transfer can be performed either as a repair of oocyte or repair of Embryo [31] [32]

In method one, the cytoplasm is withdrew from a donor’s oocyte, and then injected into a patient’s oocyte together with the sperm cells which will then fertilize the oocyte. In Method two, the cytoplasm from donor is injected into a patient’s fertilized oocyte.

Simplified Cell Structure [32]
Egg repair by Cytoplasmic transfer [32]
repair by Cytoplasmic transfer [32]

Key Events of Cytoplasmic Transfer

  • 1982, United Kingdom - Audrey Muggleton-Harris's group at MRC Laboratory Animals Center in Surrey, developed the technique and reported the first successful mammalian cytoplasmic transfer in mice [33].
  • 1982 United Kingdon - Muggleton-Harris's group transferred cytoplasm from mice strains whose oocytes divide past the two-cell stage in vitro into mice to overcome the two-cell barrier [34].
  • 1997, United States - Jacques Cohen, Richard Scott, Tim Schimmel, Jacob Levron, and Steen Willadsen at the Institute for Reproductive Medicine and Science of St. Barnabas in West Orange, New Jersey, announced the birth of a baby girl after the first successful human cytoplasmic transfer [35].
  • 1998 United States – The US Food and Drug Administration (FDA) banned the procedure.
  • 2002 United States - one of the children conceived through ooplasmic transfer were diagnosed with pervasive developmental disorder, and indicated mild developmental delays to severe autism.
  • 2014 United States - public meetings to discuss mitochondrial manipulation techniques were held by FDA. There was no formal decision made base on the efficacy of Cytoplasmic transfer, but agreements were made on further practice on animal models to provide scientific data.


Cytoplasmic transfer cases in human[36]
Type of Cytoplasm Transferred to recipient oocytes No. of Procedures Pregnancies achieved Offspring delivered
Synchronized fresh oocytes by electrofusion [37] 3 0 0
Synchronized fresh oocytes by injection (USA) [38] [39] [40] [41] [42] 30 13 16
Synchronized fresh oocytes by injection (Israel) [36] 15 5 6
Synchronized frozen oocytes by injection [43] 4 1 2
Asynchronous 3-PN zygotes by injection [44] 9 4 5

Risk of Cytoplasmic Transfer -- Heteroplasmy

Heteroplasmy is defined as the mixture of more than one Mitochondrial DNA (mtDNA) type within the cytoplasm of an individual [45] [46]. It is believed to have rare heteroplasmic mutation in healthy individuals previously. however, human mtDNA sequencing has now showed that each person has some low- frequency, slightly different mtDNA types mixed with the maternally inherited dominant type. and this low-frequency variants arise from mutations during growth and mitosis of individual cell. The two types of heteroplasmy are length heteroplasmy and sequence (or site) heteroplasmy [47] .

An example of sequence heteroplasmy visualized by partial mtDNA sequencing [48]


  • Length heteroplasmy is the presence of mtDNA molecules that differ in length.
  • Sequence (site) heteroplasmy is the presence of mtDNA molecules that have different nucleotides at the same site.


Although the low frequency mtDNA mutation is quite common and cells can contain varying proportions of mutated and wild-type mtDNA [49]. Cells can usually tolerate the level of mutations. Only if the mutation is pathogenic, and the percentage of variants exceeds the biochemical threshold, defects will be induced[50].

Cytoplasmic transfer in IVF procedure has the risk of manifesting the mutations as it combines the mtDNA from donor with the maternally inherited mtDNA of the recipient. Heteroplasmy is thus one of the major concerns arise regarding cytoplasmic transfer in IVF procedure [51]. Severe disease can occur due to heteroplasmy in the offspring’s mitochondria. They may affect the development of the muscle, brain and endocrine system [52]. They could also result in mitochondrial disease developing either in the child or in future generations [53].

Spindle-Chromosome Transfer

Spindle-choromosome transfer is a modified cloning technique which transfers the meiotic spindle and attached chromosomes (spindle-chromosome complex, SCC) from one mature oocyte to another to select for a cytoplasm or mtDNA background [54]. Comparing to cytoplasmic transfer, the advantage of spindle transfer is the reduction of heteroplasmy risk, thus offer a better reproductive option to prevent mtDNA disease transmission in affected families [55].This technology has been used to generate both cattle and mice after subsequent fertilization (Bai et al, 2006, Bao et al, 2003, Wakayama et al, 2004 and Wang et al, 2001), and has generated live monkeys (Macaca mulatta) after sperm injection [56]. Spindle transfer between human oocytes has also result in blastocyst development and embryonic stem cell derivation with very low levels of heteroplasmy [57].


What is the procedure?

Diagram of spindle-chromosomal transfer [58]
 Assisted reproductive technologies are used to extract the patient’s egg from her ovaries. The cytoplasm of the egg contains the unhealthy mitochondria. Chromosomes, the nuclear DNA material, are found in the patient’s eggs are grouped together in a spindle-like formation.


  1. The chromosomes are removed for transfer to the donor egg. The chromosome-free egg, which contains the unhealthy mitochondria, is then discarded.
  2. Separately, a donated egg is also extracted from an unrelated woman who has healthy mitochondria. Similarly, the chromosomes of the donor’s egg are removed. However, these chromosomes are discarded, leaving behind the healthy mitochondria in the cytoplasm.
  3. The spindle-like chromosomes previously taken from the patient's egg are inserted into the enucleated donor’s egg.
  4. The resulting reconstructed egg contains nuclear DNA from the mother and the healthy mitochondria from the donor.
  5. The resulting egg can now be fertilized with sperm from the intended father. The resulting embryo will be implanted into the patient and will develop unaffected by inherited mitochondrial disease.

Primate model

Due to the uncertainty of the health risks related to spindle-chromosome tranfer, experiments in non-human primates are required to access the safety of this procedue. Tachibana et al(2009) have carried out maternal spindle transfer using healthy eggs from non-human primates (rhesus macaques)[59].
  • a - removed the nuclear material plus a cellular membrane (a karyoplast) from a mature oocyte, leaving behind its mitochondria. The nuclear material in the karyoplast consists of condensed chromosomes attached to thread-like spindle fibres (the spindle–chromosomal complex).
  • b - transferred the karyoplast to an oocyte whose nucleus had been removed (a cytoplast).
  • c - fused the karyoplast with the cytoplast and then fertilized the reconstructed oocyte.
  • d - developing blastocyst was implanted in a surrogate mother.
  • e - mother gave birth to a healthy baby.

Some of the resulting embryos were successful and produced healthy offspring with low mtDNA carryover. However it is still too early to determine whether spindle-chromosome tranfer is a safe procedure. Because defects may develop later in life, or in their own offspring. Thus long-term studies are required to access the effects of this procedure, which includes life-long monitoring and multi-generational tracking.

Primate model of spindle-chromosome transfer [60]

Current Research

Currently, researchers at Newcastle University in the United Kingdom are collaborating with the Oregon researchers who successfully generated the first primate model in 2009. They are testing the maternal spindle transfer technique on human oocytes. Fertilization rate in ST oocytes (73%) was similar to controls (75%); however, a significant portion of ST zygotes (52%) showed abnormal fertilization as determined by an irregular number of pronuclei. Among normally fertilized ST zygotes, blastocyst development (62%) and embryonic stem cell isolation (38%) rates were comparable to controls. All embryonic stem cell lines derived from ST zygotes had normal euploid karyotypes and contained exclusively donor mtDNA. Thus they concluded that the mtDNA can be efficiently replaced in human oocytes, although some ST oocytes displayed abnormal fertilization[61].


Limitations

Experiments showed minimal mutated mtDNA carryover in nonhuman primate offspring and human preimplantation embryos. However, the spindle is very sensitive to micromanipulation, which frequently induces premature activation of oocytes and results in karyotype abnormalities [62] [63].

Pronuclear transfer

Pronuclear Transfer is similar to Maternal Spindle Transfer but performed as a repair of embryo. it fertilizes the mother’s egg first and then transfers the nuclear DNA to the fertilised donor egg containing healthy mitochondria, from which the original nuclear DNA has been removed [64].

  • pronuclear transfer procedures was first performed on mice in the 1990s, suggesting the possibility of preventing the transmission of mutated mitochondrial DNA [65].
  • In 2003 scientists at Sun Yat-Sen University in China first attempted this procedure on human embryos. Five genetically modified embryos were implanted into a 30-year-old woman. She became pregnant with triplets, and doctor removed one to give the other two foetuses better chance of survival. After some months, the woman suffered miscarriages and lost both foetuses [66].
  • In 2010 researchers at Newcastle University reported that pronuclear-transferred human embryos developed normally to the blastocyst stage in six to eight days, this marked the procedure as a success in preventing mitochondrial disease [67].


What is the procedure?

Diagram of pronuclear transfer [68]

The nuclear genome from the pronuclear stage zygote of an affected woman is transferred to an enucleated donor zygote [66]

  1. It begins with creating an embryo using the parents’ sperm and eggs.
  2. At the same time, a second embryo is created using a donor egg with healthy mitochondria and the father’s (or donor) sperm.
  3. The pronuclei are removed from the single-cell stage embryo (day one). The leftover enucleated embryo with diseased mitochondria is discarded.
  4. The pronuclei of the second embryo are removed and discarded.
  5. The parents’ pronuclei can be placed into the second embryo for development.
  6. The developed embryo will then be transferred into the mother.

Human Embryo Model

Research Group in New Castle University performed pronuclear transfer on human mebryo model[69]:

  • Pronuclear transfer was performed using abnormally fertilised human zygotes generated following in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI).
  • Abnormal zygotes were identified on day 1 of development by the presence of one pronucleus (unipronucleate) or three pronuclei (tripronucleate) 18-19 hours after insemination.
  • Karyoplasts containing pronuclei and surrounding cytoplasm were removed from the donor zygote using a biopsy pipette and transferred to a recipient zygote.
  • Following fusion, the reconstituted zygotes were either cultured for 6-8 days to monitor development to the blastocyst stage or were cultured before being disaggregated for analysis of mtDNA in individual blastomeres'.

The safety effects of this procedure (zygote mtDNA carry-over) were tested by sequencing of non-coding control region. The sequence of donor and recipient mtDNA were then compared. Based on the data provided, they believe pronuclear transfer has the potential to prevent the transmission of mtDNA disease in humans. However, Further studies are required to ensure the safety of different techniques when modifying human oocytes and zygotes due to the potential of causing chromosomal or epigenetic abnormalities 

Current research on pronuclear transfer  Healing Broken Batteries – A short film about mitochondrial disease and the new techniques being developed at Newcastle University.

Limitations

pronuclear transfer (PNT) between zygotes can correct mtDNA-related phenotypes in mice model. However, it is reported that PNT-generated mice possessed 6%–21% heteroplasmic mtDNA at the weaned stage, and the average increase was 12% to possess 5%–44% heteroplasmic mtDNA at Day 300 after birth [70] . Human embryo model study showed that PNT between zygotes resulted in minor donor mtDNA carryover (<2.0%) in early embryos [71]. However, one disadvantage of PNT is that the manipulation, which requires both donor and recipient fertilized eggs, discards half of the embryos.

Polar Body Transfer

Polar bodies are small cells formed during the meiotic reductive division of the oocyte. they contains complementary choromosomes (to the mature oocyte) and small amount of cytoplasmic segregation[72].
an early human zygot [73]
  • Polar body 1 is formed and released during ovulation. it contains a diploid set of chromosomes.
  • Polar body 2 is formed during fertilization and can be identified in the zygote. it contains a haploit set of chromosomes.
  • Both polar bodies are unable to be fertilized and disintegrate eventually

Due the unique feature of polar bodies, which can provide beneficial information about the genetic background of the oocyte without potentially destroying it, polar body biopsies have been applied in preimplantation genetic diagnosis to detect inheritable chromosomal or genetic abnormalitiesg. More recently, the new roles of polar bodies in assisted reproductive technology are single-cell sequencing of the polar body genome to deduce the genomic information of its sibling oocyte and the polar body transfer to prevent the transmission of mtDNA-associated diseases [74].

The advantages of polar body transfer has been reported as[75]:

  • Polar body 1 and 2 contain minimunmitochondria but carries the entire genome.
  • Polar body 1 and 2 are seperate from the oocyte thus it can be easily manipulated without damage to the chromosome.
  • each donor will have three offers (polar body 1, body 2, maternal pronucleus), which significant increase the efficiency of using donor egg.


What is the procedure?

Diagram of Polar body 1 transfer [76]
Diagram of Polar body 2 transfer [77]

Mice Model

Polar body transfer has been adopted on mice model to prevent the transmission of mtDNA variants. They also compare the effects of different types of germline genome transfer, including spindle-chromosome transfer, pronuclear transfer, and first and second polar body transfer, in mice. Their pre-clinical model indicate that polar body transfer has better potential in preventing the inheritance of mitochondrial diseases[78]. The other group coupled Polar body transfer with Pronuclei transfer or Spindle-choromosome transfer on mice model which increased the yield of reconstructed embryos with low mtDNA carryover. [79]

Other Approaches

Germinal Vesicle Nuclear Transfer

Germinal vesicle oocyte [80]


The germinal vesicle (GV) is a large nucleus of the immature oocytes arrested naturally in the first meiotic prophase. the oocyte undergoes GVBD soon after MPF activation, and its material (or nucleoplasm) mixes with the cytoplasm (or ooplasm) of maturing oocytes. The germinal vesicle contains a number of proteins, such as histones and DNA polymerases, that are used immediately after fertilization [81][82].

Germinal Vesicle Transfer (GVT) is the transfer of a GV from an unfertilised into an enucleated recipient oocyte. Following reconstruction, the GV is allowed to develop to Metaphase II through in vitro maturation (IVM) and is then fertilised through either IVF or ICSI. The resultant zygotes are then allowed to develop in culture before transfer to patients [83]. These procedures have been proposed as potential treatments for those women whose oocytes fail to fertilise or arrest during development or are associated with aneuploidy. Studies using human oocytes have shown that GVT from aged oocytes introduced into the enucleated ooplasm of young oocytes or sibling oocytes can overcome oocyte aneuploidy, and produced the majority of reconstructions with normal karyotypes[84] [85].

Similar to the other techniques,A major concern of GVT is still that the transferred GV is still surrounded by a population of tightly packed mitochondria which will also be introduced into the donor ooplasm. These mitochondria remain close to center of the immature reconstruction and disperse throughout the cytoplasm as maturation ensues[83].

Ethics

Some people believe that the Mitochondrial Gene Transfer techniques are ethical. The Nuffield Council on Bioethics in the UK examined the ethical issues and wrote in a report that “Due to the health and social benefits to individuals and families of living free from mitochondrial disorders, … we believe that if these novel techniques are adequately proven to be acceptably safe and effective as treatments, it would be ethical for families to use them, if they wish to do so and have been offered an appropriate level of information and support.”. [86]

Others hold an opposite opinion. They believe that children born with Mitochondrial Gene Transfer techniques would have a genetic connection to three parents due to the fact that such therapies involve modification of the germline.

1.PMID 26239841 The ethical challenges of the clinical introduction of mitochondrial replacement techniques. [87] The first part of the paper evaluates the three concerns about the safety of mitochondrial replacement techniques including whether it is ethical; persons with three genetic contributors and the trust of society. And then, two recommendations are made.

2.PMID 21059727 Ethics of mitochondrial gene replacement: from bench to bedside. [88] Both of the risks and benefits are accessed in this paper after the briefly introduction of mitochondrial replacement techniques. And then the question of when are enough safeguards made to justify introducing mitochondrial gene replacement into the clinic is discussed.

3.PMID 25888328 Mitochondrial replacement to prevent the transmission of mitochondrial DNA disease. [89] This paper discussed about the ethics and feasibility of mitochondrial replacement techniques. The possibility of preventing the transmission of mtDNA disease by MRT is first discussed. Moreover, the four big challenges mainly ethics are discussed.

Legal Status

Permitted

Britain is the only country in the world legally allows the inheritable genetic modification of humans. On February 24, 2015, the House of Lords approved regulations. Earlier in the month, the UK House of Commons also approved the techniques that would create an embryo with genetic material from three different people and result in inheritable genetic modification, with 382 votes in favor and 128 against. [90]

Under Discussion

In USA, the legality of mitochondrial manipulation techniques is still under discussion. On February 25 and 26, 2014, public meetings that included discussion of mitochondrial manipulation techniques were held by The US Food and Drug Administration (FDA). None of the seven public spoke who had contacted the FDA in advance in favor of the techniques. There was no formal decision made base on the efficacy of Cytoplasmic transfer, but agreements were made on further practice on animal models to provide scientific data. On January 27 2015, the Institute of Medicine (IOM) held the first in a series of meetings to fulfill the FDA’s request to consider the Ethical and Social Policy of Novel Techniques for Prevention of Maternal Transmission of Mitochondrial DNA Diseases.

Prohibited

Region Country Laws

Asia

 Cyprus Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine
Georgia Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine
India National Guidelines for Accreditation, Supervision & Regulation of ART Clinics in India

Ethical Policies on the Human Genome, Genetic Research and Services by Department of Biotechnology

Guidelines for Stem Cell Research

Japan Act on Regulation of Human Cloning Techniques (Act No. 146 of 2000) / ヒトに関するクローン技術等の規制に関する法律（平成十二年十二月六日法律第百四十六号）


Oceania

 Australia Prohibition of Human Cloning for Reproduction and the Regulation of Human Embryo Research Amendment Act 2006
New Zealand Human Assisted Reproductive Technology Act 2004

Europe

 Austria The Act on Reproductive Medicine / Bundesgesetz, mit dem Regelungen über die medizinisch unterstützte Fortpflanzung getroffen (Fortpflanzungsmedizingesetz — FMedG)
Belgium Law on Research into Embryos in Vitro / PROJET DE LOI relatif à la recherche sur les embryons in vitro / WETSONTWERP betreffende het onderzoek op embryo’s in vitro

Law on Medically Assisted Reproduction and the Disposition of Supernumerary Embryos and Gametes / PROJET DE LOI relatif à la procréation médicalement assistée et à la destination des embryons surnuméraires et des gamètes / WETSONTWERP betreffende de medisch egeleide voortplanting en de bestemming van de overtallige embryo's en de gameten

Bosnia and Herzegovina Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine
Bulgaria Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine
Croatia Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine
Czech Republic Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine
Denmark Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine
Estonia Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine
France Bioethics Law No. 2004-800 / Loi n° 2004-800 du 6 août 2004 relative à la bioéthique

Law on the Donation and Use of Elements and Products of the Human Body, Medically Assisted Procreation, and Prenatal Diagnosis, No. 94-654 / Loi n° 94-654 du 29 juillet 1994 relative au don et à l'utilisation des éléments et produits du corps humain, à l'assistance médicale à la procréation et au diagnostic prénatal

Germany Act for Protection of Embryos(The Embryo Protection Act) / Gesetz zum Schutz von Embryonen (Embryonenschutzgesetz – ESchG)

Adoption Brokerage Law 2006 / Gesetz über die Vermittlung der Annahme als Kind und uber das Verbot der Vermittlung von Ersatzmüttern

Hungary Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine
Iceland Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine
Italy Medically Assisted Procreation Law / Norme in materia di procreazione medicalmente assistita
Lithuania Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine
Malta Embryo Protection Act
Moldova Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine
Netherlands Act Containing Rules Relating to the Use of Gamete and Embryos / Embryowet
Norway Act of 5 December 2003 No. 100 relating to the application of biotechnology in human medicine, etc
Romania Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine
San Marino Convention for the Protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine
Spain Law on Assisted Human Reproduction Techniques, No. 14/2006 / Ley 14/2006, de 26 de mayo, Sobre Téchnicas de Reproducción Humana Asistida.

Biomedicine Law 14/2007. Ley 14/2007, de 3 de Julio, de Investigación Biomédica

Sweden Act on Ethics Review of Research Involving Humans, Law No. 460 (2003). Law (2003: 460) / om etikprövning av forskning som avser människor. Svenska författningssamling 2003: 460

Genetic Integrity Act, Law No. 351 (2006). Law (2006: 351) / om genetisk integritet m.m. Svenska författningssamling 2006: 351

Switzerland Federal Act on Medically Assisted Reproduction / Bundesgesetz über die medizinisch unterstützte Fortpflanzung

Federal Act on Research Involving Embryonic Stem Cells / Federal Act on Research Involving Embryonic Stem Cells

America

 Canada Assisted Human Reproduction Act (S.C. 2004, c. 2)
Uruguay Law Regulating Human Assisted Reproductive Techniques No.19167 / Ley 19.167 – Técnicas de reproducción humana asistida. Regulación

Africa

 South Africa National Health Act 2003 (ACT NO.61, 2003)
Region Country Laws


Further Reading

useful publications:

PMID 23608245 The ethics of creating children with three genetic parents. [91]

PMID 24382342 Three-Parent IVF: Gene Replacement for the Prevention of Inherited Mitochondrial Diseases.[92]

PMID 20933103 Mitochondrial function in the human oocyte and embryo and their role in developmental competence.[93]

PMID 26020522 Mitochondrial reshaping accompanies neural differentiation in the developing spinal cord.[94]

PMID 25421171 The impact of mitochondrial function/dysfunction on IVF and new treatment possibilities for infertility.[95]

PMID 25807984 Risks inherent to mitochondrial replacement.[96]

Glossary

Maternal Spindle Transfer: The transfer of nuclear DNA from a patient egg into a donor egg with its nuclear DNA removed, which is then fertilized and implanted via standard IVF.

Ooplasmic Transfer: The injection of ooplasm from a donor egg into a patient egg. Leads to mitochondrial heteroplasmy.

Pronuclear Transfer: The pre-fertilized nuclear DNA form a patient is transferred into a donor egg with its nuclear DNA removed, which is then fertilized and implanted via standard IVF.

References

  1. ↑ GeoBeats News. (20131, December 19) Teenage Girl Has Three Biological Parents. Retrieved from https://youtu.be/0Zs2KntZ7vU
  2. ↑ <pubmed> 6896904 </pubmed>
  3. ↑ <pubmed> 6896904 </pubmed>
  4. ↑ <pubmed> 3201231 </pubmed>
  5. ↑ <pubmed> 2830540 </pubmed>
  6. ↑ <pubmed> 9039911 </pubmed>
  7. ↑ <pubmed> 9250192</pubmed>
  8. ↑ <pubmed> 9250192 </pubmed>
  9. ↑ <pubmed> 9674999 </pubmed>
  10. ↑ <pubmed> 19710649 </pubmed>
  11. ↑ <pubmed>20393463</pubmed>
  12. ↑ <pubmed> 2830540 </pubmed>
  13. ↑ <pubmed> 16814712 </pubmed>
  14. ↑ <pubmed> 19651984 </pubmed>
  15. ↑ <pubmed> 25629662 </pubmed>
  16. ↑ <pubmed>25539952</pubmed>
  17. ↑ <pubmed>18651330</pubmed>
  18. ↑ <pubmed>23385875</pubmed>
  19. ↑ <pubmed>25038129</pubmed>
  20. ↑ <pubmed> 24382342</pubmed>
  21. ↑ <pubmed> 25573721 </pubmed>
  22. ↑ <pubmed> 24382342</pubmed>
  23. ↑ <pubmed>24373414</pubmed>
  24. ↑ <pubmed> 25229667 </pubmed>
  25. ↑ <pubmed> 23103869 </pubmed>
  26. ↑ <pubmed> 15140871 </pubmed>
  27. ↑ <pubmed> 3352746 </pubmed>
  28. ↑ <pubmed> 10429238 </pubmed>
  29. ↑ J A.Barritt, S Willadsen Epigenetic and experimental modifications in early mammalian development: part II Cytoplasmic transfer in assisted reproduction Human Reproduction Update 2001 Vol.7, No.4 pp.428-435
  30. ↑ <pubmed> 23602680 </pubmed>
  31. ↑ <pubmed> 24382342</pubmed>
  32. ↑ 32.0 32.1 32.2 32.3 Charlotte Pritchard The girl with three biological parents1 September 2014 http://www.bbc.com/news/magazine-28986843 retrieved September 2015
  33. ↑ <pubmed> 6896904 </pubmed>
  34. ↑ <pubmed> 6896904 </pubmed>
  35. ↑ <pubmed> 9250192</pubmed>
  36. ↑ 36.0 36.1 J A.Barritt, S Willadsen Epigenetic and experimental modifications in early mammalian development: part II Cytoplasmic transfer in assisted reproduction Human Reproduction Update 2001 Vol.7, No.4 pp.428-435
  37. ↑ <pubmed> 9570273 </pubmed>
  38. ↑ <pubmed> 9250192 </pubmed>
  39. ↑ <pubmed> 9570273 </pubmed>
  40. ↑ <pubmed> 10973657 </pubmed>
  41. ↑ <pubmed>11228222 </pubmed>
  42. ↑ <pubmed>11041526</pubmed>
  43. ↑ <pubmed>10065803</pubmed>
  44. ↑ <pubmed>10521114</pubmed>
  45. ↑ <pubmed>20735895</pubmed>
  46. ↑ <pubmed>24135157</pubmed>
  47. ↑ <pubmed>23271951</pubmed>
  48. ↑ <pubmed>23271951</pubmed>
  49. ↑ <pubmed>23077218</pubmed>
  50. ↑ <pubmed>23271951</pubmed>
  51. ↑ <pubmed>16939888</pubmed>
  52. ↑ <pubmed>26281784</pubmed>
  53. ↑ <pubmed>24709341</pubmed>
  54. ↑ <pubmed>25444504</pubmed>
  55. ↑ <pubmed>23103867</pubmed>
  56. ↑ <pubmed> 25573721 </pubmed>
  57. ↑ <pubmed> 25973765 </pubmed>
  58. ↑ <pubmed> 25573721 </pubmed>
  59. ↑ <pubmed> 19710649 </pubmed>
  60. ↑ <pubmed> 19710649 </pubmed>
  61. ↑ <pubmed> 23103867</pubmed>
  62. ↑ <pubmed> 25472922</pubmed>
  63. ↑ <pubmed> 23254936</pubmed>
  64. ↑ <pubmed>25573721</pubmed>
  65. ↑ Mado Vandewoestyne , Jitesh Neupane , Björn Heindryckx , Sylvie Lierman ,Dieter Deforce and Petra De Sutter (2012) Pronuclear transfer in mice yields minimal mitochondrial DNA carry-over Mado Vandewoestyne FERTILITY AND STERILITY. 98(3, suppl.). p.S289-S289
  66. ↑ 66.0 66.1 Three-Parent Baby Pioneer Jamie Grifo: The Brits Will be Ahead of the World 16 January 2015 http://www.geneticsandsociety.org/article.php?id=8314. Retrived 15 Oct 2015
  67. ↑ <pubmed> 20393463</pubmed>
  68. ↑ <pubmed> 25573721 </pubmed>
  69. ↑ <pubmed> 20393463 </pubmed>
  70. ↑ <pubmed>16275929</pubmed>
  71. ↑ <pubmed>20393463</pubmed>
  72. ↑ <pubmed> 24949971 </pubmed>
  73. ↑ Hill, M.A. (2015) Embryology Early zygote labelled.jpg. Retrieved October 16, 2015, from https://embryology.med.unsw.edu.au/embryology/index.php/File:Early_zygote_labelled.jpg
  74. ↑ <pubmed> 25472922 </pubmed>
  75. ↑ <pubmed> 25472922 </pubmed>
  76. ↑ <pubmed> 25472922 </pubmed>
  77. ↑ <pubmed> 25472922 </pubmed>
  78. ↑ <pubmed> 24949971 </pubmed>
  79. ↑ <pubmed> 25573721 </pubmed>
  80. ↑ <pubmed>19924284</pubmed>
  81. ↑ <pubmed> 12193404 </pubmed>
  82. ↑ <pubmed> 21234179 </pubmed>
  83. ↑ 83.0 83.1 Scientific and Clinical Advances Group 24 Nov 2005 Germinal vesicle transfer SCAG(11/05)04 retrieved from http://www.hfea.gov.uk/docs/SCAG_Germinal_vesicle_transfer_nov05.pdf at 16 Oct 2015
  84. ↑ <pubmed>25985993</pubmed>
  85. ↑ <pubmed>25515532</pubmed>
  86. ↑ http://nuffieldbioethics.org/project/mitochondrial-dna-disorders/
  87. ↑ <pubmed>26239841</pubmed>
  88. ↑ <pubmed>21059727</pubmed>
  89. ↑ <pubmed>25888328</pubmed>
  90. ↑ Gallagher, James (03 February 2015) MPs say yes to three-person babies BBC News Retrieved 09 October 2015.
  91. ↑ <pubmed> 23608245</pubmed>
  92. ↑ <pubmed> 24382342</pubmed>
  93. ↑ <pubmed> 20933103 </pubmed>
  94. ↑ <pubmed> 26020522 </pubmed>
  95. ↑ <pubmed> 25421171</pubmed>
  96. ↑ <pubmed> 25807984</pubmed>

External Links

Retrieved from ‘https://embryology.med.unsw.edu.au/embryology/index.php?title=2015_Group_Project_1&oldid=207459’
Powered by MediaWiki